
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Medication Pearl of the Day: Lacosamide (Vimpat)
Lacosamide is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, as well as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
Insight:
Sources:






